The failure to discuss potential harms of more widespread testing in more than a general way is a significant omission in this story.
With some wording changes and a few more statistics, this pretty good story about aspirin for cancer prevention would have become demonstrably better.
This bare-bones report on a drug trial was probably aimed at investors — but will almost certainly reach consumers as well. We think both groups would be interested in the very high cost of this drug combination.
FoxNews.com labels this piece as “news” – not as an opinion piece by one physician. To use the columnist’s own words in a different context, “I find this outrageous.”
The short piece in the Washington Post’s “To Your Health” blog was also short on useful information. Our review highlights some areas where the story could have deployed its limited text more effectively.
This is a case where the body text of the story sends one message, but the headline and photos send a different one.
This story embraces a study’s finding that “women aren’t getting enough” omega-3s during pregnancy. We thought the story could have provided more context with that message.
Less than half of the patients who participated in a group stress management program 11 years ago were recruited into a long-term follow-up study of their outcomes. We thought that key limitation deserved some discussion in this story about the study.